EIF5B

Across TCGA pan-cancer cohorts, EIF5B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF5B data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF5B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EIF5B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where EIF5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.698	1.000	.001	45	view →
LUAD	DFS	Median	III,IV	0.996	0.485	.001	34	view →
LSCC	OS	Tertile	All	0.952	0.667	.001	34	view →
GBM	DFS	Median	All	0.275	0.461	.008	6	view →
PDAC	OS	Quartile	All	0.859	0.972	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF5B–CCRCC (OS)

Open the CCRCC breakdown →